CPAP management of COVID-19 respiratory failure: a first quantitative analysis from an inpatient service evaluation.
Abdul AshishAlison UnsworthJane MartindaleRam SundarKanishka KavuriLuigi SeddaMartin FarrierPublished in: BMJ open respiratory research (2020)
CPAP is a simple and cost-effective intervention. It has been established for care of other respiratory disorders but not for COVID-19 respiratory failure. This evaluation establishes that CPAP as a potentially viable treatment option for this group of patients during the first days of hospital admission. As yet there is limited availability of quantitative research on CPAP use for COVID-19. Whist this work is hampered by both the relatively small sample size and retrospective design (which reduced the ability to control potential confounders), it represents evidence of the significant benefit of early CPAP intervention. This evaluation should stimulate further research questions and larger study designs on the potential benefit of CPAP for COVID-19 infections. Globally, this potentially beneficial low cost and low intensity therapy could have added significance economically for healthcare provision in less developed countries.
Keyphrases
- obstructive sleep apnea
- respiratory failure
- coronavirus disease
- positive airway pressure
- sars cov
- healthcare
- sleep apnea
- extracorporeal membrane oxygenation
- low cost
- randomized controlled trial
- mechanical ventilation
- palliative care
- ejection fraction
- newly diagnosed
- respiratory syndrome coronavirus
- emergency department
- end stage renal disease
- stem cells
- high resolution
- acute respiratory distress syndrome
- prognostic factors
- cell therapy
- intensive care unit
- mass spectrometry
- health information
- social media
- combination therapy
- adverse drug